Phase I clinical trial study on biochemically recurrent PC using DNA vaccines that encode prostatic acid phosphatase (PAP) plus GM-CSF (pTVG-HP) showed that the vaccination was safe, and CD4+ and/or CD8+ PAP specific responses were developed in some patients (106). This evidence concerns the gene CD8A and pachyonychia congenita.